GLP1s Increase Rick Of Cancer?

About this video

Gillett raises a cautious, explicitly unsettled question about GLP-1 medicines and cancer, focusing on thyroid cancer. He says the evidence is mixed, with analyses pointing in different directions, and argues it is premature for anyone — especially those who profit from prescribing — to declare there is no risk. He links his concern mechanistically to growth-related signaling, draws parallels with historical enthusiasm for growth hormone, and contrasts two scenarios: he argues sustained weight loss likely lowers overall cancer risk, while repeated cycles of loss and regain could, in his view, compound metabolic harm. He stresses large long-term studies are lacking for many popular peptide uses.

Key takeaways

• Hold mixed evidence as mixed, and be skeptical of anyone declaring zero risk with certainty
• Notice financial interests when a prescriber dismisses safety questions outright
• Prioritize keeping weight off over repeated cycles of loss and regain, which Gillett argues are especially damaging
• Remember that popularity of a peptide class is not a substitute for large long-term safety studies
• Separate a drug’s proven benefits in serious disease from casual cosmetic use in healthy people

Episode details: published January 13, 2024 · 294 views · 5:25 long. Summary written by Self Growth Videos from the episode itself. The hormone, metabolic and peptide concepts described are Dr. Kyle Gillett’s, presented for education — not medical advice. Consult a qualified professional before changing your own health practices. Disclosure: Gillett Health is a clinical practice that treats these conditions.

← Previous: Type 1 Diabetes | The Gillett Health Podcast · Next: GLP1 Update | The Gillett Health Podcast #59 →

All Dr. Kyle Gillett videos · Dr. Kyle Gillett profile · Gillett Health (official site)